Skip to main content
. 2020 Jun 13;12(6):1566. doi: 10.3390/cancers12061566

Figure 1.

Figure 1

Minimal residual disease (MRD) monitoring and early diagnosis of relapse. Liquid biopsy approaches might be well suited to measuring MRD, as residual tumor components can be detected with high sensitivity. Because MRD-positive patients have higher risk of relapse, early diagnosis of relapse may improve patient outcomes. This figure reflects a representative case of our own original data.